Composition and method for pipeline conditioning and freezing point suppression

Information

  • Patent Grant
  • 8065905
  • Patent Number
    8,065,905
  • Date Filed
    Friday, June 22, 2007
    17 years ago
  • Date Issued
    Tuesday, November 29, 2011
    13 years ago
Abstract
Method for dewatering, pressure testing, hydrotreating, suppressing methane hydrate formation and suppressing solution freezing point in pipeline operations have been disclosed, where the solution used in the operations includes an effective amount of a metal formate salt. The metal formate salt solutions have a low viscosity, have a high density, have a low metals corrosivity, are non-volatile, have a low solubility in hydrocarbons, are readily biodegradable, have a low toxicity, are non-hazardous, have a low environmental impact, have a freezing point depression property forming water/formate eutectic point mixtures, and have a water-structuring and water activity modification property.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to a method and a use of an aqueous, metal ion formate salt composition for reducing a residual water film on an interior of a pipeline during pipeline dewatering operations, which may involve the use of a pig or a plurality of pigs, for pipeline pressure testing operations, for freezing pointing suppression for sub-freezing temperature pipeline testing operations, i.e., operation at temperatures below 0° C.


More particularly, the present invention relates to a method and a use of an aqueous metal ion formate salt composition for pipeline operations. The method includes the step of contacting an interior of a pipeline with an effective amount of an aqueous metal ion formate salt composition, where the effective amount is sufficient to reduce substantially all or part of a residual water film from the interior of the pipeline during a dewatering operation. The metal ion formate salt composition includes a concentration of metal ion formate salt sufficient to dilute a water concentration of a residual film in a pipeline formed during a dewatering operation, where the dewatering operation may involve the use of a pig or multiple pigs. The present invention also relates to a method and a use of an aqueous metal ion formate salt composition in pipeline pressure testing operations. In sub-freezing point operations, the composition includes an amount of the metal ion formate salt sufficient to suppress a freezing point of fluid during repair and/or pressure testing operations to a desired temperature below a freezing point of ordinary water. The present invention also relates to a method and a use of an aqueous metal ion formate salt composition in all other sub-freezing temperature operations, including wet hydrocarbon transmission in sub-freezing temperature environments.


2. Description of the Related Art


Large volumes of methanol and glycol are routinely injected into gas transport pipelines to inhibit the formation of gas hydrates. These chemicals are derived from hydrocarbons and pose a potential environmental risk for the user. Companies commonly apply conditioning agents such as these for pipeline pre-commissioning operations.


Thermodynamic gas hydrate inhibitors are widely used for a number of applications. They essentially reduce the equilibrium temperature of hydrate formation by acting on the chemical potential of water in the aqueous phase. Chemicals such as methanol and glycol which fall into this category are generally dosed at relatively high concentrations (10-15% w/w) in the aqueous phase. Methanol is, on mass basis the most efficient of the conventional thermodynamic hydrate inhibitors. It is cheap and readily available, but it is a volatile chemical and losses of the inhibitor to the hydrocarbon phase can be considerable. In addition, the handling of methanol is complicated by its toxicity and flammability. While ethylene glycols are far less flammable, and their losses in the hydrocarbon phase are lower, they possess similar toxicity issues.


Despite the widespread use of brines in drilling fluids as gas hydrate inhibitors they are rarely used in pipelines. This is because conventional brines are corrosive, prone to crystallization and generally less effective than either methanol or glycol.


Pipelines that are used for transportation of hydrocarbon gases should be free of water. There are various reasons for this including: (1) prevention of hydrate formation, (1) prevention or reduction of corrosion, and (3) meeting gas sale specifications. Newly constructed pipelines are typically hydrotested; it is, therefore, necessary to dewater and condition the pipeline. This often involves the use of “conditioning” chemicals such as ethylene glycol or other similar glycols or methanol. These chemicals present the industry with certain toxicity problems, which prevents them from being discharged into marine environments. Further, methanol presents another problem; it is highly flammable in air.


Thus, there is a need in the art for an improved system and method for dewatering and conditioning pipelines and for a new fluid for use in repair and pressure testing at temperatures below the freezing point of pure water, which are environmentally friendly and have similar thermodynamic hydrate inhibition properties and similar freezing point suppressant properties compared to methanol and glycols.


SUMMARY OF THE INVENTION

The present invention provides an improved system for dewatering and conditioning pipelines, where the system includes an aqueous composition comprising an effective amount of a metal ion formate salt, where the effective amount is sufficient to reduce an amount of bulk water and/or an amount of residual water in the pipeline, to reduce an amount of a residual water film in a pipeline below a desired amount or to remove substantially all of the residual water in the pipeline.


The present invention also provides a method for dewatering a pipeline including the step of pumping an aqueous composition comprising an effective amount of metal ion formate salt, where the effective amount is sufficient to reduce an amount of a residual water film in the pipeline, to reduce an amount of the residual water film in a pipeline below a desired amount or to remove substantially the residual water film in the pipeline. The method can also include the step of pumping the spent solution into a marine environment without pretreatment. The method can also include the step of pressure testing the pipeline with an aqueous fluid including a metal ion formate salt in a concentration sufficient to reduce or eliminate hydrate formation after pressuring testing and during initial hydrocarbon production. In sub-freezing point operation, the concentration of the metal ion formate salt is sufficient to lower the freezing point of the fluid to a desired temperature below the freezing point of pure water so that the pressure testing or hydrotesting can be performed when the ambient temperature is below the freezing point of pure water (a sub-freezing temperature) without a concern for having to clean up material lost from leaks.


The present invention also provides a method for pressure testing a pipeline including the step of filling a pipeline or a portion thereof with an aqueous composition including a metal ion formate salt, where the composition is environmentally friendly, i.e., capable of being released into a body of water without treatment. The method is especially well suited for pressuring testing a pipeline at sub-freezing temperatures, where an effective amount of the metal ion formate salt is added to the aqueous composition to depress the composition's freezing point temperature to a temperature below the operating temperature, where operating temperature is below the freezing point of pure water.


The present invention also provides a method for installing a pipeline including the step of filling a pipeline with an aqueous metal ion formate salt composition of this invention. After the pipeline is filled, the pipeline is laid, either on a land site or a subsea site. After laying the pipeline, the pipeline is pressurized using an external water source. After pressure testing, the pipeline is brought on production by displacing the composition and the pressuring external water, which can be discharged without treatment. In certain embodiments, the pipeline is laid subsea and the pressurizing external water is seawater, where the composition and pressurizing seawater are discharged into the sea as it is displaced by production fluids. By using the composition of this invention, hydrate formation is precluded during the composition displacement operation. In certain embodiments, the pressure testing is performed at a pressure that is a percentage of the maximum allowable operating pressure or a specific percentage of the pipeline design pressure. In other embodiments, the pressure testing is performed at a pressure between about 1.25 and about 1.5 times the operating pressure. Of course, an ordinary artisan would understand that the pressure testing can be at any desired pressure.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention can be better understood with reference to the following detailed description together with the appended illustrative drawings in which like elements are numbered the same.



FIG. 1 depicts a plot of hydrate suppression of a potassium formate solution of this invention compared to a methanol solution and an ethylene glycol solution.



FIG. 2 depicts a plot of freezing point suppression versus salt concentration in wt. % for various salts including potassium formate.



FIG. 3 depicts a plot of freezing point suppression versus salt concentration in ions:water, mol/mol for various salts including potassium formate.



FIG. 4 depicts a plot of freezing point suppression versus various concentrations of potassium formate.



FIG. 5 depicts hydrate suppression using potassium formate at various concentrations.





DEFINITIONS USED IN THE INVENTION

The term “substantially” means that the actual value is within about 5% of the actual desired value, particularly within about 2% of the actual desired value and especially within about 1% of the actual desired value of any variable, element or limit set forth herein.


The term “residual film” means a water film left in a pipeline after a pig bulk dewatering operation. For carbon steel pipelines, a water residual film of about 0.1 mm is left in the pipeline. The present composition is used to change the make up of the residual film coating the pipeline to a film having at least 70% w/w of the aqueous, metal ion formate salt composition of this invention and 30% w/w residual water. In certain embodiments, the residual film comprises at least 80% w/w of the aqueous, metal ion formate salt composition of this invention and 20% w/w residual water. In certain embodiments, the residual film comprises at least 90% w/w of the aqueous, metal ion formate salt composition of this invention and 10% w/w residual water. In certain embodiments, the residual film comprises at least 95% w/w of the aqueous, metal ion formate salt composition of this invention and 5% w/w residual water. In certain embodiments, the residual film comprises at least 99% w/w of the aqueous, metal ion formate salt composition of this invention and 1% w/w residual water. Of course, for other pipeline materials, the film make up can vary, but generally it will be within these ranges. Of course, the final make up of the residual film coating the pipeline will depend on operating conditions and is adjusted so that the water content is below a dew point of pure water under the operating conditions.


The term “formate” means the salt of formic acid HCOO.


The term “metal ion formate salt” means the salt of formic acid HCOOHM+, where M+ is a metal ion.


The term “sub-freezing temperature” means a temperature below the freezing point of pure water.


DETAILED DESCRIPTION OF THE INVENTION

The inventors have found that a new fluid can be formulated for use in pipeline dewatering, conditioning, pressuring testing, and/or sub-freezing temperature testing operations, where the new fluid is capable of being used without environmental consideration. The new fluid includes an aqueous solution including a metal ion formate. These solutions are well suited for pipeline dewatering operations, pipeline repair operations, pipeline pressure testing operations, pipeline conditioning operations, pipeline hydrotesting operations or other pipeline operations without being concerned with collecting and disposing of the fluid as is true for competing fluids such as glycol containing fluids or alcohol containing fluids. The new fluid is also especially well suited for sub-freezing temperature operations.


The inventors have found that metal ion formate solutions such as potassium formate, marketed as Superdry 2000 by Weatherford International, is an alternative for many pipeline water removal or sub-freezing temperature applications. The formate solutions have similar conditioning properties to currently used fluids such as methanol and glycols, without the hazards associated with methanol and glycols. Formate solutions, such as potassium formate solutions, are known to be non-toxic and suitable for discharge directly into marine environments, without further processing. The ability to discharge formate solutions directly into marine environments is of particular benefit as it avoids the handling of typically large volumes of methanol or glycol containing fluids. In addition, metal ion formates lower the freezing point of water so that these solutions are suitable for use in low temperature applications, where freeze point suppression is needed, e.g., pressure testing or hydrotesting pipelines when the ambient temperature is below the freezing point of water or other sub-freezing temperature pipeline operations.


Metal ion formate salts, such as potassium formate, are very soluble in water forming a brine system, especially a concentrated brine system, with unique fluid properties. These properties include (1) a low viscosity, (2) a high density, (3) a low metals corrosivity, (4) low volatility, (5) a low solubility in hydrocarbons, (6) readily biodegradable, (7) a low toxicity, (8) nonhazardous, (9) a low environmental impact, (10) a freezing point depression property forming water/formate eutectic point mixtures, and (11) a water-structuring and water activity modification property.


The inventors have found that metal ion formate salts are soluble in water up to their saturation point, which is about 75% w/w in water for potassium formate. Metal ion formate salt solutions, including from about 5% w/w of a metal ion formate salt to water up to a saturated or supersaturated aqueous solution of the metal ion formate salt solutions, are well suited as powerful hydrate inhibitors comparable to conventional inhibitors. Of course, the concentration of the brine system needed for any given application will depend on the operation being undertaken or on the sub-freezing temperature operation being undertaken.


Potassium formate solutions display similar low viscosities as monoethylene glycol. Potassium formate solutions have low hydrocarbon solubility and have a specific gravity of about 1.57. Thus, in a two-phase system, metal ion formate salt solutions will more readily migrate with the heavier aqueous phase than compared with inhibitors such as methanol and glycol, which have substantial solubilities in hydrocarbons.


With an alkaline pH in the range of 10, concentrated metal ion formate salt solutions exhibit very low corrosivity to metals, while hydrocarbons and hazardous volatile organics have a very low solubility in the concentrated formate solutions at high pH, further reducing the corrosive effects of such organics, which often cause corrosive problems in other aqueous fluids, which tend to absorb the volatile compounds such as carbon dioxide, hydrogen sulfide, thiols, sulfides, hydrogen cyanide, etc.


Although not all metal ion formate salt solutions have been toxicity tested, potassium formate solutions are categorized as nonionic, non flammable and are rated nonhazardous for transport and handling purposes. The nontoxic properties of potassium formate solutions extend to aquatic organisms, where these solutions are readily biodegradable in dilute solution or acts as a biostat in concentrated solutions. Thus, the formulations of this invention have an OCNS Category E rating in Europe.


Potassium formate solutions have been subject to Mysidopsis bahia and Menidia beryllina larval survival and growth toxicity testing in an 800 mg/L control solution. Both microorganisms passed the normality tests at this concentration. The toxicity limit for subsea fluids in the OCS General Permit (GMG 290000) requires the survival NOEC to be ≧50 mg/L. The testing performed was an order of magnitude, i.e., 16 times greater than the permit requirements.


Further, metal ion formate salt solutions display similar eutectic properties to glycol-water solutions. For example, a 50% w/w solution of potassium formate in water has a freezing point of around −60° C.


It is common practice to condition deepwater pipelines using fluids such as glycols or methanol. The former is more common because it does not have the safety issues associated with the low vapor pressures of methanol. Such fluids are used to mitigate the risk of forming methane hydrates during startup operations. Methane hydrates form under certain pressure and temperature conditions. In deepwater systems, these conditions can exist at the extremities of the pipeline. High well head operating pressures and low subsea temperatures are perfect conditions for the creation of hydrates. Thus, it is common practice to heavily dose the tree with methanol or glycol during startup as a mitigating measure in the prevention of hydrate formation. This dosing is typically performed in conjunction with a chemical swabbing dewatering operation, and provides the pipeline with adequate protection throughout the system to prevent the formation of hydrates. However, dosing during startup on a pipeline system that has been “bulk dewatered” (i.e., unconditioned with chemicals) can still result in the formation of a hydrate. Hydrate formation in this setting is due to the initial adiabatic drop in pressure occurring across the well in conjunction with a high flowrate, and thus, methane gas may come into contact with free water further upstream of the chemical injection point. In such instances hydrates may form.


Many operators wish to avoid the use of hydrocarbon-based chemistry for this application, but as a general rule these systems are widely used due to lack of viable alternatives. The metal ion formate salt solutions of this invention provide the operators with an environmentally friendly, viable alternative with the added benefit that hydrate formation is mitigated during startup operations. Further, the metal ion formate salt solutions of this invention are also more cost effective than traditional fluids, because capture and subsequent disposal of the treating fluid is not required. The metal ion formate salt solutions can be discharged overboard in accordance with the relevant MMS permits.


Thus, the present invention also provides a method for conditioning deepwater pipelines comprising the step of filling the pipeline with an aqueous composition including an effective amount of a metal ion formate salt, where the effective amount is sufficient to reduce gas hydrate formation, especially methane hydrate formation.


The metal ion formate salt compositions of this invention are ideally suited for replacing traditional chemicals used in pig dewatering operations such as methanol and glycols, which have toxicity issued and must be treated or recovered. In dewatering operations, a pig or a pig train, where a pig train includes at least two pigs. In pig trains, the dewatering operation also includes at least one slug of a pipeline residual water film treatment introduced between at least two adjacent pigs. The lead pig or pigs push out the bulk water in the pipeline. However, remaining on the surface of the pipeline interior wall is a film of water. The film thickness will vary depending on the type of metal used to make the pipeline and on the tolerance of the pig-pipeline match. The slug of treatment is adapted to reduce or eliminate the water film or to replace the film with a film comprising at least 70% w/w of a formate salt composition of this invention. Other embodiments of film composition are listed above. The pig train can include a number of pigs with a number of treatment slugs traveling with the train between adjacent pigs. In certain embodiments, at least two slugs of treatment are used. The first treatment slug changes the film make up and pulls out excess water, while subsequent slugs dilute the film make up to a desired low amount of water. As set forth above, the low amount of water is less than about 30% w/w with the formate salt composition comprising the remainder. In other embodiments, the low amount of water is less than about 20% w/w. In yet other embodiments, the low amount of water is less than about 10% w/w. In still other embodiments, the low amount of water is less than about 5% w/w. It should be recognized that in actuality the formate solution is being diluted by the water and the film is becoming a diluted formate salt film. However, the goal of these treatments is to change the film composition sufficiently to reduce a dew point of the remaining water in the film below a dew point of water or seawater at the operating conditions. Therefore, the amount of formate composition will be sufficient to achieve this desired result. Of course, the amount of formate composition needed will also depend on the initial concentration of formate salt in the composition. In many dewatering embodiments, the initial formate composition will be a saturated or slightly supersaturated formate composition, where the term slight supersaturated means that the composition contains about 0.1 to 5% formate salt in excess of the saturation concentration, where residual water will dilute the formate concentration into a saturated or sub-saturated formate composition.


Suitable Reagents


Suitable metal ions for use in this invention include, without limitation, alkali metal ions, alkaline metal ions, transition metal ions, lanthanide metal ions, and mixtures or combinations thereof. The alkali metal ions are selected from the group consisting of Li+, Na+, K+, Rd+, Cs+, and mixtures or combinations thereof. The alkaline metal ions are selected from the group consisting of Mg2+, Ca2+, Sr2+, Ba2+ and mixtures or combinations thereof. In certain embodiments, the transition metal ions are selected from the group consisting of Ti4+, Zr4+, Hf4+, Zn2+ and mixtures or combinations thereof. In certain embodiments, the lanthanide metal ions are selected from the group consisting of La3+, Ce4+, Nd3+, Pr2+, Pr3+, Pr4+, Sm2+, Sm3+, Gd3+, Dy2+, Dy3+, and mixtures or combinations thereof.


Suitable metal ion formate salts for use in this invention include, without limitation, a compound of the general formula (HCOO)nMn+ and mixtures or combinations thereof, where M is a metal ion as set forth above and n is the valency of the metal ion.


Compositional Ranges


For dewatering applications, the general concentration range of metal ion formate salt in water is between about 40% w/w to saturation. In certain embodiments, the concentration range of metal ion formate salt in water is between about 45% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 50% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 55% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 60% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 65% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 70% w/w to saturation. Of course one of ordinary art would understand that the concentration will depend on the required reduction in the amount of bulk and/or residual water left in the pipeline. In certain embodiments, the amount of metal ion formate salt in water can result in a supersaturated solution, where residual water in the pipeline will dilute the solution form supersaturated to saturated or below during the dewatering operation.


For sub-freezing pipeline applications, the general concentration range of metal ion formate salt in water is between about 5% w/w to saturation. In certain embodiments, the concentration range of metal ion formate salt in water is between about 15% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 25% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 35% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 45% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 55% w/w to saturation. In other embodiments, the concentration range of metal ion formate salt in water is between about 65% w/w to saturation. Of course, one of ordinary art would understand that the concentration will depend on the sub-freezing temperature needed for the application and the concentration can be adjusted dynamically to depress the freezing point to a temperature at least 5% below the sub-freezing operating temperature. In certain embodiments, the concentration of metal ion formate salt is sufficient to depress the freezing point to a temperature at least 10% below the sub-freezing operating temperature. In certain embodiments, the concentration of metal ion formate salt is sufficient to depress the freezing point to a temperature at least 15% below the sub-freezing operating temperature. In certain embodiments, the concentration of metal ion formate salt is sufficient to depress the freezing point to a temperature at least 20% below the sub-freezing operating temperature.


EXPERIMENTS OF THE INVENTION

Referring now to FIG. 1, a plot of methane hydrate suppression properties with methanol, ethylene glycol and potassium formate. The data shows that the potassium formate solution of this invention suppresses hydrate formation to an extent between ethylene glycol and methanol. Thus, the potassium formate solution of this invention is well suited for the suppression of methane hydrate in pipelines, especially during startup operations.


Referring now to FIG. 2, a plot of freezing point suppression verses salt concentration in wt. % for various salts including potassium formate.


Referring now to FIG. 3, a plot of freezing point suppression verses salt concentration in ions:water, mol/mol for various salts including potassium formate.


Referring now to FIG. 4, a plot offreezing point suppression verses various concentrations of potassium formate.


Referring now to FIG. 5, a plot of hydrate suppression using potassium formate at various concentrations.


The above data clearly shows that metal ion formate salts are well suited for dewatering, testing, hydrotesting, hydrate suppression, and/or sub-freezing temperature pipeline operations.


All references cited herein are incorporated by reference. Although the invention has been disclosed with reference to its preferred embodiments, from reading this description those of skill in the art may appreciate changes and modification that may be made which do not depart from the scope and spirit of the invention as described above and claimed hereafter.

Claims
  • 1. A method for hydrotesting or pressure testing pipelines comprising the step of: filling a pipeline or a portion thereof with an aqueous composition including an effective amount of a metal ion formate salt,pressurizing the pipeline to a pressure between about 1.25 and about 1.5 times an operating pressure of the pipeline without a concern for having to clean up material lost from leaks, anddischarging the aqueous composition directly into the environment after the pressurizing, without further processing or treatment,where the effective amount is sufficient to reduce an amount of bulk water and/or an amount of residual water in the pipeline below desired amounts and to depress a freezing point temperature of the composition to a temperature below an operating temperature of the pipeline, where operating temperature is below the freezing point of pure water.
  • 2. The method of claim 1, wherein the metal ion formate salt is a compound of the formula (HCOO−)nMn+ and mixtures thereof, where M is a metal ion and n is the valency of the metal ion.
  • 3. The method of claim 2, wherein the metal ion is selected from the group consisting of an alkali metal ion, an alkaline metal ion, a transition metal ion, a lanthanide metal ion, and mixtures thereof.
  • 4. The method of claim 3, wherein the alkali metal ion is selected from the group consisting of Li+, Na+, K+, Rd+, Cs+, and mixtures thereof.
  • 5. The method of claim 4, wherein the alkali metal ion is K+.
  • 6. The method of claim 3, the alkaline metal ion is selected from the group consisting of Mg2+, Ca2+, Sr2+, Ba2+ and mixtures thereof.
  • 7. The method of claim 3, wherein the transition metal ion is selected from the group consisting of Ti4+, Zr4+, Hf4+, Zn2+ and mixtures thereof.
  • 8. The method of claim 3, wherein the lanthanide metal ion is selected from the group consisting of La3+, Ce4+, Nd3+, Pr2+, Pr3+, Pr4+, Sm2+, Sm3+, Gd3+, Dy2+, Dy3+, and mixtures thereof.
  • 9. The method of claim 1, wherein the effective amount is at least about 5% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 10. The method of claim 1, wherein the effective amount is at least about 25% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 11. The method of claim 1, wherein the effective amount is at least about 45% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 12. The method of claim 1, wherein the effective amount is at least about 65% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 13. The method of claim 1, wherein effective amount comprises a saturated or slightly supersaturated formate composition so that the amount of residual water will dilute the formate concentration into a saturated or sub-saturated formate composition.
  • 14. A system for use in conditioning and/or pressure testing pipelines comprising an aqueous composition comprising an effective amount of a metal ion formate salt, where the aqueous composition fills a pipeline or portion thereof, where the pipeline or portion thereof is pressurized to a pressure between about 1.25 to about 1.5 times an operating pressure of the pipeline, where the effective amount is sufficient to reduce an amount of bulk water and/or an amount of residual water in the pipeline below desired amounts and/or to depress a freezing point of the aqueous composition to a temperature below an operating temperature of a pipeline to be conditioned or tested, where the operating temperature of the pipeline is below the freezing point of pure water, and where the aqueous composition is directly discharged into the environment without further processing or treatment.
  • 15. The system of claim 14, wherein the effective amount is sufficient to remove substantially all of the bulk water and residual water in the pipeline.
  • 16. The system of claim 14, wherein the metal ion formate salt is a compound of the formula (HCOO−)nMn+ and mixtures thereof, where M is a metal ion and n is the valency of the metal ion.
  • 17. The system of claim 16, wherein the metal ion is selected from the group consisting of an alkali metal ion, an alkaline metal ion, a transition metal ion, a lanthanide metal ion, and mixtures thereof.
  • 18. The system of claim 17, wherein the alkali metal ion is selected from the group consisting of Li+, Na+, K+, Rd+, Cs+, and mixtures thereof.
  • 19. The system of claim 18, wherein the alkali metal ion is K+.
  • 20. The system of claim 17, wherein the alkaline metal ion is selected from the group consisting of Mg2+, Ca2+, Sr2+, Ba2+ and mixtures thereof.
  • 21. The system of claim 17, wherein the transition metal ion is selected from the group consisting of Ti4+, Zr4+, Hf4+, Zn2+ and mixtures thereof.
  • 22. The system of claim 17, wherein the lanthanide metal ion is selected from the group consisting of La3+, Ce4+, Nd3+, Pr2+, Pr3+, Pr4+, Sm2+, Sm3+, Gd3+, Dy2+, Dy3+, and mixtures thereof.
  • 23. The system of claim 14, wherein the effective amount is at least about 5% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 24. The system of claim 14, wherein the effective amount is at least about 25% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 25. The system of claim 14, wherein the effective amount is at least about 45% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 26. The system of claim 14, wherein the effective amount is at least about 65% w/w of metal ion formate salt to water and a saturation solution of the metal ion formate salt in water.
  • 27. The system of claim 14, wherein effective amount comprises a saturated or slightly supersaturated formate composition so that the amount of residual water will dilute the formate concentration into a saturated or sub-saturated formate composition.
US Referenced Citations (362)
Number Name Date Kind
2074047 Dechant Mar 1937 A
2196042 Timpson Apr 1940 A
2390153 Kern Dec 1945 A
3018695 George Jan 1962 A
3059909 Wise Oct 1962 A
3163219 Wyant et al. Dec 1964 A
3292698 Savins Dec 1966 A
3301723 Chrisp Jan 1967 A
3301848 Halleck Jan 1967 A
3303896 Tillotson et al. Feb 1967 A
3317430 Priestley et al. May 1967 A
3361213 Savins Jan 1968 A
3373107 Rice et al. Mar 1968 A
3406115 White Oct 1968 A
3565176 Wittenwyler Feb 1971 A
3578871 Sakamoto May 1971 A
3604508 Son, Jr. Sep 1971 A
3760881 Kiel Sep 1973 A
3849348 Hewitt Nov 1974 A
3856921 Shrier et al. Dec 1974 A
3888312 Tiner et al. Jun 1975 A
3892252 Poettmann Jul 1975 A
3920599 Hurlock et al. Nov 1975 A
3933205 Kiel Jan 1976 A
3937283 Blauer et al. Feb 1976 A
3954627 Dreher et al. May 1976 A
3960736 Free et al. Jun 1976 A
3965982 Medlin Jun 1976 A
3990978 Hill Nov 1976 A
4007792 Meister Feb 1977 A
4049608 Steckler et al. Sep 1977 A
4052159 Fuerst et al. Oct 1977 A
4061580 Jahnke Dec 1977 A
4064091 Samour et al. Dec 1977 A
4067389 Savins Jan 1978 A
4071457 Meister Jan 1978 A
4108782 Thompson Aug 1978 A
4112050 Sartori et al. Sep 1978 A
4112051 Sartori et al. Sep 1978 A
4112052 Sartori et al. Sep 1978 A
4113631 Thompson Sep 1978 A
4120356 Meister Oct 1978 A
4148736 Meister Apr 1979 A
4192753 Pye et al. Mar 1980 A
4324669 Norman et al. Apr 1982 A
4337185 Wessling et al. Jun 1982 A
4360061 Center et al. Nov 1982 A
4378845 Medlin et al. Apr 1983 A
4409110 Borchardt et al. Oct 1983 A
4412586 Sifferman Nov 1983 A
4416297 Wolfram et al. Nov 1983 A
4418755 Sifferman Dec 1983 A
4432881 Evani Feb 1984 A
4438045 Nieh et al. Mar 1984 A
4458757 Bock et al. Jul 1984 A
4461716 Barbarin et al. Jul 1984 A
4465801 Peiffer et al. Aug 1984 A
4469873 Nieh Sep 1984 A
4479041 Fenwick et al. Oct 1984 A
4506734 Nolte Mar 1985 A
4507210 Lauzon Mar 1985 A
4514309 Wadhwa Apr 1985 A
4517351 Szymanski et al. May 1985 A
4534875 Rose Aug 1985 A
4541935 Constien et al. Sep 1985 A
4549608 Stowe et al. Oct 1985 A
4561984 Bresson et al. Dec 1985 A
4569799 House Feb 1986 A
4579667 Echt et al. Apr 1986 A
4579670 Payne Apr 1986 A
4591447 Kubala May 1986 A
4604217 Lukach et al. Aug 1986 A
4615825 Teot et al. Oct 1986 A
4617132 Dalrymple Oct 1986 A
4623021 Stowe Nov 1986 A
4637883 Patel et al. Jan 1987 A
4646834 Bannister Mar 1987 A
4653584 Ball et al. Mar 1987 A
4654266 Kachnik Mar 1987 A
4657081 Hodge Apr 1987 A
4660643 Perkins Apr 1987 A
4662444 Yang May 1987 A
4681165 Bannister Jul 1987 A
4683068 Kucera Jul 1987 A
4686052 Baranet et al. Aug 1987 A
4695389 Kubala Sep 1987 A
4702848 Payne Oct 1987 A
4705113 Perkins Nov 1987 A
4707306 Leighton et al. Nov 1987 A
4710586 Patel Dec 1987 A
4714115 Uhri Dec 1987 A
4718490 Uhri Jan 1988 A
4724905 Uhri Feb 1988 A
4725372 Teot et al. Feb 1988 A
4735731 Rose et al. Apr 1988 A
4737296 Watkins Apr 1988 A
4739834 Peiffer et al. Apr 1988 A
4741401 Walles et al. May 1988 A
4743384 Lu et al. May 1988 A
4748011 Baize May 1988 A
4770814 Rose et al. Sep 1988 A
4778865 Leighton et al. Oct 1988 A
4779680 Sydansk Oct 1988 A
4790958 Teot Dec 1988 A
4795574 Syrinek et al. Jan 1989 A
4796702 Scherubel Jan 1989 A
4806256 Rose et al. Feb 1989 A
4817717 Jennings, Jr. et al. Apr 1989 A
4830106 Uhri May 1989 A
4831092 Bock et al. May 1989 A
4834182 Shu May 1989 A
4846277 Khalil et al. Jul 1989 A
4848468 Hazlett et al. Jul 1989 A
4852650 Jennings, Jr. et al. Aug 1989 A
4852652 Kuehne Aug 1989 A
4869322 Vogt, Jr. et al. Sep 1989 A
4880565 Rose et al. Nov 1989 A
4892147 Jennings, Jr. et al. Jan 1990 A
4910248 Peiffer Mar 1990 A
4911241 Williamson et al. Mar 1990 A
4926940 Stromswold May 1990 A
4938286 Jennings, Jr. Jul 1990 A
4948576 Verdicchio et al. Aug 1990 A
4975482 Peiffer Dec 1990 A
4978512 Dillon Dec 1990 A
4988450 Wingrave et al. Jan 1991 A
5005645 Jennings, Jr. et al. Apr 1991 A
5024276 Borchardt Jun 1991 A
5036136 Peiffer Jul 1991 A
5049383 Huth et al. Sep 1991 A
5062969 Holtmyer et al. Nov 1991 A
5067556 Fudono et al. Nov 1991 A
5074359 Schmidt Dec 1991 A
5074991 Weers Dec 1991 A
5082579 Dawson Jan 1992 A
5093448 Peiffer Mar 1992 A
5101903 Lave et al. Apr 1992 A
5105884 Sydansk Apr 1992 A
5106518 Cooney et al. Apr 1992 A
5110486 Manalastas et al. May 1992 A
5125456 Hutchins et al. Jun 1992 A
H001077 Peiffer et al. Jul 1992 H
5129457 Sydansk Jul 1992 A
5137715 Hoshowski et al. Aug 1992 A
5162475 Tang et al. Nov 1992 A
5169411 Weers Dec 1992 A
5169441 Lauzon Dec 1992 A
5203411 Dawe et al. Apr 1993 A
5224546 Smith et al. Jul 1993 A
5228510 Jennings, Jr. et al. Jul 1993 A
5246072 Frazier, Jr. et al. Sep 1993 A
5246073 Sandiford et al. Sep 1993 A
5258137 Bonekamp et al. Nov 1993 A
5259455 Nimerick et al. Nov 1993 A
5276248 Engelhardt et al. Jan 1994 A
5310002 Blauch et al. May 1994 A
5330005 Card et al. Jul 1994 A
5342530 Aften et al. Aug 1994 A
5347004 Rivers et al. Sep 1994 A
5362827 Bock Nov 1994 A
5363919 Jennings, Jr. Nov 1994 A
5402846 Jennings, Jr. et al. Apr 1995 A
5411091 Jennings, Jr. May 1995 A
5424284 Patel et al. Jun 1995 A
5439055 Card et al. Aug 1995 A
5462689 Choy et al. Oct 1995 A
5462721 Pounds et al. Oct 1995 A
5465792 Dawson et al. Nov 1995 A
5472049 Chaffee et al. Dec 1995 A
5482116 El-Rabaa et al. Jan 1996 A
5483986 Onan et al. Jan 1996 A
5488083 Kinsey, III et al. Jan 1996 A
5497831 Hainey et al. Mar 1996 A
5501275 Card et al. Mar 1996 A
5529122 Thach Jun 1996 A
5547026 Brannon et al. Aug 1996 A
5551516 Norman et al. Sep 1996 A
5562866 Hu et al. Oct 1996 A
5566760 Harris Oct 1996 A
5587356 Dauderman et al. Dec 1996 A
5591701 Thomas Jan 1997 A
5597783 Audibert et al. Jan 1997 A
5607904 Jarrett Mar 1997 A
5624886 Dawson et al. Apr 1997 A
5635458 Lee et al. Jun 1997 A
5637556 Argillier et al. Jun 1997 A
5649596 Jones et al. Jul 1997 A
5652200 Davies et al. Jul 1997 A
5669447 Walker et al. Sep 1997 A
5670460 Neely et al. Sep 1997 A
5674377 Sullivan, III et al. Oct 1997 A
5679877 Erilli et al. Oct 1997 A
5688478 Pounds et al. Nov 1997 A
5693837 Smith et al. Dec 1997 A
5701955 Frampton Dec 1997 A
5705467 Choy Jan 1998 A
5706895 Sydansk Jan 1998 A
5707955 Gomes et al. Jan 1998 A
5711376 Sydansk Jan 1998 A
5711396 Joerg et al. Jan 1998 A
5722490 Ebinger Mar 1998 A
5725636 Gavlin et al. Mar 1998 A
5728654 Dobson, Jr. et al. Mar 1998 A
5735349 Dawson et al. Apr 1998 A
5741757 Cooper et al. Apr 1998 A
5744024 Sullivan, III et al. Apr 1998 A
5755286 Ebinger May 1998 A
5767050 Adamy et al. Jun 1998 A
5775425 Weaver et al. Jul 1998 A
5785747 Vollmer et al. Jul 1998 A
5787986 Weaver et al. Aug 1998 A
5806597 Tjon-Joe-Pin et al. Sep 1998 A
5807812 Smith et al. Sep 1998 A
5833000 Weaver et al. Nov 1998 A
5846308 Lauzon Dec 1998 A
5846450 Atkinson Dec 1998 A
5853048 Weaver et al. Dec 1998 A
5871049 Weaver et al. Feb 1999 A
5877127 Card et al. Mar 1999 A
5908073 Nguyen et al. Jun 1999 A
5908814 Patel et al. Jun 1999 A
5964295 Brown et al. Oct 1999 A
5965502 Balzer Oct 1999 A
5979555 Gadberry et al. Nov 1999 A
5979557 Card et al. Nov 1999 A
5980845 Cherry Nov 1999 A
6011075 Parris et al. Jan 2000 A
6016871 Burts, Jr. Jan 2000 A
6020289 Dymond Feb 2000 A
6035936 Whalen Mar 2000 A
6047772 Weaver et al. Apr 2000 A
6054417 Graham et al. Apr 2000 A
6059034 Rickards et al. May 2000 A
6060436 Snyder et al. May 2000 A
6063737 Haberman et al. May 2000 A
6068056 Frenier et al. May 2000 A
6069118 Hinkel et al. May 2000 A
6076046 Vasudevan et al. Jun 2000 A
6100222 Vollmer et al. Aug 2000 A
6103153 Park et al. Aug 2000 A
6106700 Collins et al. Aug 2000 A
6110451 Matz et al. Aug 2000 A
6123394 Jeffrey Sep 2000 A
6133205 Jones Oct 2000 A
6140277 Tibbles et al. Oct 2000 A
6143709 Carey Nov 2000 A
6147034 Jones et al. Nov 2000 A
6156805 Smith et al. Dec 2000 A
6162449 Maier et al. Dec 2000 A
6162766 Muir et al. Dec 2000 A
6169058 Le et al. Jan 2001 B1
6172010 Argillier et al. Jan 2001 B1
6192985 Hinkel et al. Feb 2001 B1
6194354 Hatchman Feb 2001 B1
6194356 Jones et al. Feb 2001 B1
6221817 Guskey et al. Apr 2001 B1
6227295 Mitchell et al. May 2001 B1
6228812 Dawson et al. May 2001 B1
6230805 Vercaemer et al. May 2001 B1
6232274 Hughes et al. May 2001 B1
6239183 Farmer et al. May 2001 B1
6247543 Patel et al. Jun 2001 B1
6248317 Snyder et al. Jun 2001 B1
6258859 Dahayanake et al. Jul 2001 B1
6267938 Warrender et al. Jul 2001 B1
6268314 Hughes et al. Jul 2001 B1
6279656 Sinclair et al. Aug 2001 B1
6281180 Tartakovsky et al. Aug 2001 B1
6283212 Hinkel et al. Sep 2001 B1
6284230 Sako et al. Sep 2001 B1
6291405 Lee et al. Sep 2001 B1
6297203 Guskey et al. Oct 2001 B1
6302209 Thompson et al. Oct 2001 B1
6305470 Woie Oct 2001 B1
6306800 Samuel et al. Oct 2001 B1
6315824 Lauzon Nov 2001 B1
6330916 Rickards et al. Dec 2001 B1
6350721 Fu et al. Feb 2002 B1
6359040 Buidick Mar 2002 B1
6399546 Chang et al. Jun 2002 B1
6399547 Frenier et al. Jun 2002 B1
6403537 Chesser et al. Jun 2002 B1
6410489 Zhang et al. Jun 2002 B1
6417268 Zhang et al. Jul 2002 B1
6432885 Vollmer Aug 2002 B1
6433075 Davies et al. Aug 2002 B1
6446727 Zemlak et al. Sep 2002 B1
6454005 Smith Sep 2002 B1
6468945 Zhang Oct 2002 B1
6474413 Barbosa et al. Nov 2002 B1
6482866 Dahayanake et al. Nov 2002 B1
6488091 Weaver et al. Dec 2002 B1
6489270 Vollmer et al. Dec 2002 B1
6491099 Di Lullo Arias et al. Dec 2002 B1
6506710 Hoey et al. Jan 2003 B1
6508307 Almaguer Jan 2003 B1
6509300 Gupta Jan 2003 B1
6509301 Vollmer Jan 2003 B1
6534449 Gilmour et al. Mar 2003 B1
6569814 Brady et al. May 2003 B1
6573305 Thunhorst et al. Jun 2003 B1
6575242 Woie Jun 2003 B2
6579947 Heitz et al. Jun 2003 B2
6586371 Maroy et al. Jul 2003 B1
6605570 Miller et al. Aug 2003 B2
6719053 Thompson Apr 2004 B2
6725931 Nguyen et al. Apr 2004 B2
6756345 Pakulski et al. Jun 2004 B2
6767867 Chatterji et al. Jul 2004 B2
6793018 Dawson et al. Sep 2004 B2
6832650 Nguyen et al. Dec 2004 B2
6844296 Dawson et al. Jan 2005 B2
6875728 Gupta et al. Apr 2005 B2
6896718 Hallman May 2005 B2
7093655 Atkinson Aug 2006 B2
7140433 Gatlin et al. Nov 2006 B2
7183239 Smith et al. Feb 2007 B2
7268100 Kippie et al. Sep 2007 B2
7350579 Gatlin et al. Apr 2008 B2
20020002205 Dahayanake et al. Jan 2002 A1
20020004464 Nelson et al. Jan 2002 A1
20020033260 Lungwitz et al. Mar 2002 A1
20020049256 Bergeron, Jr. Apr 2002 A1
20020056828 Hallman May 2002 A1
20020125012 Dawson et al. Sep 2002 A1
20020129641 Tucker et al. Sep 2002 A1
20020132741 Chang et al. Sep 2002 A1
20020147114 Dobson, Sr. et al. Oct 2002 A1
20020165308 Kinniard et al. Nov 2002 A1
20020185278 Brown et al. Dec 2002 A1
20020189810 DiLullo et al. Dec 2002 A1
20020193257 Lee et al. Dec 2002 A1
20030008779 Chen et al. Jan 2003 A1
20030008781 Gupta et al. Jan 2003 A1
20030008803 Nilsson et al. Jan 2003 A1
20030019627 Qu et al. Jan 2003 A1
20030040441 Miller et al. Feb 2003 A1
20030040546 Dahayanake et al. Feb 2003 A1
20030045605 Thompson Mar 2003 A1
20030057401 Craig Mar 2003 A1
20030073585 Di Lullo Arias et al. Apr 2003 A1
20030119680 Chang et al. Jun 2003 A1
20030130133 Vollmer Jul 2003 A1
20030134751 Lee et al. Jul 2003 A1
20030139298 Fu et al. Jul 2003 A1
20030220204 Baran, Jr. et al. Nov 2003 A1
20040091408 Hjørnevik et al. May 2004 A1
20040142825 Jovancicevic et al. Jul 2004 A1
20040198611 Atkinson Oct 2004 A1
20050045330 Nguyen et al. Mar 2005 A1
20050092489 Welton et al. May 2005 A1
20050137114 Gatlin et al. Jun 2005 A1
20050153846 Gatlin Jul 2005 A1
20050250666 Gatlin et al. Nov 2005 A1
20060194700 Gatlin et al. Aug 2006 A1
20070003371 Yemington Jan 2007 A1
20070032693 Gatlin et al. Feb 2007 A1
20070129257 Kippie et al. Jun 2007 A1
20070131425 Gatlin et al. Jun 2007 A1
20070173413 Lukocs et al. Jul 2007 A1
20070173414 Wilson, Jr. Jul 2007 A1
20080039345 Kippie et al. Feb 2008 A1
Foreign Referenced Citations (65)
Number Date Country
200221299 May 2005 AU
1185779 Apr 1985 CA
2125513 Jan 1995 CA
2007965 Feb 1996 CA
2257697 Dec 1998 CA
2257699 Dec 1998 CA
4027300 May 1992 DE
0 280 341 Aug 1988 EP
0 474 284 Mar 1992 EP
0 681 016 Nov 1995 EP
0730018 Sep 1996 EP
0 835 983 Apr 1998 EP
1 042 425 Nov 2002 EP
1 273 756 Jan 2003 EP
1 051 452 Mar 2003 EP
775376 Oct 1954 GB
816337 Jul 1959 GB
1073338 Jun 1967 GB
10001461 Jun 1988 JP
08151422 Nov 1996 JP
10110115 Apr 1998 JP
2005194148 Jul 2005 JP
WO 0211874 Jan 2002 WO
WO 9720741 Jun 1997 WO
WO 9726310 Jul 1997 WO
WO 9726311 Jul 1997 WO
WO 9819774 May 1998 WO
WO 9856497 Dec 1998 WO
WO 9932572 Jul 1999 WO
WO 9938931 Aug 1999 WO
WO 9950529 Oct 1999 WO
WO 9950530 Oct 1999 WO
WO 0032711 Jun 2000 WO
WO 0039241 Jul 2000 WO
WO 0040667 Jul 2000 WO
WO 0065196 Nov 2000 WO
WO 0078890 Dec 2000 WO
WO 0123703 Apr 2001 WO
WO 0123801 Apr 2001 WO
WO 0129369 Apr 2001 WO
WO 0151767 Jul 2001 WO
WO 0163090 Aug 2001 WO
WO 0164809 Sep 2001 WO
WO 0177487 Oct 2001 WO
WO 0181499 Nov 2001 WO
WO 0183946 Nov 2001 WO
WO 0194742 Dec 2001 WO
WO 0211873 Feb 2002 WO
WO 0224771 Mar 2002 WO
WO 0225058 Mar 2002 WO
WO 02055843 Jul 2002 WO
WO 02064946 Aug 2002 WO
WO 02064947 Aug 2002 WO
WO 02066790 Aug 2002 WO
WO 02070862 Sep 2002 WO
WO 02088520 Nov 2002 WO
WO 02096574 Dec 2002 WO
WO 03015523 Feb 2003 WO
WO 0224831 Mar 2003 WO
WO 03018695 Mar 2003 WO
WO 03048267 Jun 2003 WO
WO 03050387 Jun 2003 WO
WO 03054352 Jul 2003 WO
WO 03056130 Jul 2003 WO
WO 0212673 Feb 2004 WO
Related Publications (1)
Number Date Country
20080314124 A1 Dec 2008 US